Ibuprofen Side Effects: Common, Serious & FDA Warnings
Based on 279,000+ FDA adverse event reports, the most-reported ibuprofen reactions include pain, fatigue, and nausea. FDA reports 5 active Class II recalls of ibuprofen, primarily for failed dissolution specifications. The FDA-approved label does not carry a boxed warning.
Common Side Effects of Ibuprofen
The most-reported reactions in the FDA Adverse Event Reporting System (FAERS) for ibuprofen. Percentages reflect the share of reports mentioning each reaction; a single report may include multiple reactions. Reports indicate co-occurrence, not causation.
| Reaction | Reports | % of total |
|---|---|---|
| Pain | 19,279 | 6.9% |
| Fatigue | 18,495 | 6.6% |
| Nausea | 17,968 | 6.4% |
| Headache | 16,347 | 5.8% |
| Arthralgia | 13,263 | 4.7% |
| Dyspnoea | 12,938 | 4.6% |
| Vomiting | 12,850 | 4.6% |
| Diarrhoea | 12,545 | 4.5% |
| Dizziness | 11,268 | 4.0% |
| Rash | 10,996 | 3.9% |
Serious Outcomes and FDA Warnings
FAERS reports flagged with a serious outcome (death, hospitalization, life-threatening, disability, or congenital anomaly), plus reactions surfaced in the FDA-approved label's Warnings section. Reports indicate co-occurrence, not causation.
| Outcome flag | Reports | % of total |
|---|---|---|
| Serious reports (any flag) | — | — |
| Hospitalization | — | — |
Ibuprofen Recalls
FDA enforcement actions matched to ibuprofen via openFDA's structured generic_name field and the NDC bridge. Ongoing recalls are listed below (verify on FDA →); closed recalls are grouped in the disclosure that follows.
| Date | Reason | Class | Quantity | Status |
|---|---|---|---|---|
| 2026-03-25 | Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product. STRIDES PHARMA INC | Class II | 89592 bottles | Ongoing |
| 2024-11-27 | Failed Tablet/Capsule Specifications Dr. Reddy's Laboratories, Inc. | Class III | 3416 botttles | Ongoing |
| 2024-09-04 | Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit. Dr. Reddy's Laboratories, Inc. | Class II | 14940 bottles | Ongoing |
| 2024-09-04 | Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit. Dr. Reddy's Laboratories, Inc. | Class II | 31,802 bottles | Ongoing |
| 2024-09-04 | Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit. Dr. Reddy's Laboratories, Inc. | Class II | 103,298 bottles | Ongoing |
Show 15 closed recalls (2018 to 2022)
Includes resolved and terminated recalls matched to ibuprofen. Most recent first.
| Date | Reason | Class | Quantity | Status |
|---|---|---|---|---|
| 2022-06-15 | cGMP deviations: Temperature abuse Mckesson Medical-Surgical Inc. Corporate Office | Class II | 1 carton/100 blisters per carton | Terminated |
| 2021-06-02 | CGMP Deviations: Intermittent exposure to temperature excursion during storage. Cardinal Health Inc. | Class II | 345 CARTONS | Terminated |
| 2020-11-11 | Labeling Not Elsewhere Classified: Ibuprofen Oral Suspension is missing dosing cups. Aurobindo Pharma USA Inc. | Class III | 7440 bottles | Terminated |
| 2020-04-01 | Labeling: Lacks Warning or Rx Legend- Certain lots does not include required safety warning information in the Drug Facts Panel. Glaxosmithkline Consumer Healthcare Holdings | Class II | 151,056 bottles | Terminated |
| 2020-04-01 | Labeling: Lacks Warning or Rx Legend- Certain lots does not include required safety warning information in the Drug Facts Panel. Glaxosmithkline Consumer Healthcare Holdings | Class II | 446,628 bottles | Terminated |
| 2019-11-06 | Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing. Taro Pharmaceuticals U.S.A., Inc. | Class II | 5,190 bottles | Terminated |
| 2019-11-06 | Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing. Taro Pharmaceuticals U.S.A., Inc. | Class II | 182,986 bottles | Terminated |
| 2019-11-06 | Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing. Taro Pharmaceuticals U.S.A., Inc. | Class II | 639,325 bottles | Terminated |
| 2019-11-06 | Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing. Taro Pharmaceuticals U.S.A., Inc. | Class II | 138,886 bottles | Terminated |
| 2018-09-05 | Labeling Error: Not elsewhere classified. product has a dosage cup marked in teaspoons and the instructions on the label are described in milliliters. Pfizer Global Supply | Class II | 17,136 bottles | Terminated |
| 2018-05-02 | CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. Time-Cap Laboratories, Inc. | Class II | N/A | Terminated |
| 2018-05-02 | CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. Time-Cap Laboratories, Inc. | Class II | N/A | Terminated |
| 2018-05-02 | CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. Time-Cap Laboratories, Inc. | Class II | N/A | Terminated |
| 2018-05-02 | CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. Time-Cap Laboratories, Inc. | Class II | N/A | Terminated |
| 2018-05-02 | CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. Time-Cap Laboratories, Inc. | Class II | N/A | Terminated |
Ibuprofen Shortages
FDA-listed shortages of ibuprofen products. Strength and dosage-form level detail.
Is Ibuprofen Safe?
Ibuprofen is FDA-approved and the label does not carry a boxed warning.
As with any prescription, the assessment of safety is individual; consult a clinician about your own risk profile.
FDA-Approved Indications
Ibuprofen is FDA-approved for use in the condition categories below. The FDA-approved label’s Indications and Usage section is shown verbatim.
Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever
Frequently Asked Questions
What are the most-reported side effects of ibuprofen?
Is ibuprofen the same as Sound Body Ibuprofen?
Has ibuprofen been recalled?
What are ibuprofen's current ongoing recalls about?
What do FDA recall classes mean?
Data Sources & Methodology
How each section of this page is sourced, and how often the data is refreshed.
| Source | Endpoint | Refresh |
|---|---|---|
| FAERS reactions | openFDA /drug/event.json count API. Aggregated per drug per reaction term; we do not store individual reports. | Daily |
| Recalls | openFDA /drug/enforcement.json. Drugs matched via three confidence-tracked strategies: structured generic name (HIGH), NDC code bridge (MEDIUM), text token parse (LOW). Only HIGH and MEDIUM matches surface here. | 6 hours |
| Shortages | FDA Drug Shortages list. | Daily |
| Boxed warnings & label sections | openFDA /drug/label.json. Labels are stable; monthly cadence is sufficient. | Monthly |
| Condition categories | Synonym-mapped from drug_labels.indications. Methodology at /methodology/. | Per-drug |
What we do not do. We do not invent, paraphrase, or extrapolate drug claims. Every figure on this page comes from a query against an openFDA endpoint. If the data is unavailable, the section gracefully omits rather than filling the space with editorial guesswork.